A5019885124- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Adrenal and Paraganglionic Tumors
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Colorectal Cancer Surgical Treatments
- Intraperitoneal and Appendiceal Malignancies
- Hormonal Regulation and Hypertension
- CRISPR and Genetic Engineering
- Lung Cancer Research Studies
- Trauma and Emergency Care Studies
- Nanofabrication and Lithography Techniques
- Abdominal Trauma and Injuries
- Colorectal and Anal Carcinomas
- Congenital Diaphragmatic Hernia Studies
- Pneumothorax, Barotrauma, Emphysema
- Eicosanoids and Hypertension Pharmacology
- Diagnosis and treatment of tuberculosis
- Monoclonal and Polyclonal Antibodies Research
- Poisoning and overdose treatments
- Cardiac, Anesthesia and Surgical Outcomes
National Cancer Institute
2019-2023
Center for Cancer Research
2021-2023
National Institutes of Health
2021-2023
Johnson University
2022-2023
Rutgers, The State University of New Jersey
2023
Rutgers Sexual and Reproductive Health and Rights
2023
Maimonides Medical Center
2016
BACKGROUND. Therapeutic vaccinations against cancer have mainly targeted differentiation antigens, cancer-testis and overexpressed antigens thus far resulted in little clinical benefit. Studies conducted by multiple groups demonstrated that T cells recognizing neoantigens are present most cancers offer a specific highly immunogenic target for personalized vaccination.
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to their single-cell transcriptomes, we identified signatures CD8
Background Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering T cells tumor-reactive T-cell receptors (TCRs) comes to forefront clinical investigation, rapid, scalable, and cost-effective detection patient-specific neoantigen-reactive TIL remains a top priority. Methods We analyzed single-cell transcriptomic states 31...
Background: Peritoneal carcinomatosis historically has a poor prognosis; however, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have shown improved outcomes. While volume-outcome relationship is established in oncologic surgeries, its applicability to CRS/HIPEC remains unexplored. This study examines the impact of hospital volume on Methods: Using national Vizient Clinical Database, this retrospective analysis evaluated 5,165 HIPEC cases from 149 hospitals...
Background Synthetic cannabinoids are a recreational drug that can cause toxicity with significant side effects. Case We report 21-year-old incarcerated male delayed presentation of pneumothorax, pneumomediastinum, and pneumoperitoneum following synthetic cannabinoid use altered mental status. Discussion This case not only highlights the need to consider pneumothorax when evaluating but it also emphasizes vulnerable population (incarcerated individuals at risk for trauma, substance...
Abstract The adoptive transfer of tumor-infiltrating lymphocytes (TILs) expanded in vitro can mediate regressions established tumors, yet only a minority intratumoral T cells are reactive to cancer antigens while the majority represent bystander cells. This complexity underpins need phenotypically characterize infiltrating tumor microenvironment. In this study, we performed single-cell RNA and cell receptor (TCR) sequencing (scRNA/TCR-seq) on over 45,000 isolated from ten archival metastatic...
Abstract Adoptive cell therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from rare mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on TP53 mutations commonly shared across different cancer types. Here, describe a library T receptors (TCRs) that target among 7.3% solid cancers. These TCRs recognized tumor cells mutation- and human leucocyte antigen (HLA)-specific...
<h3>Background</h3> Autologous patient T cells engineered to express antitumor cell receptors (TCRs) and chimeric antigen (CARs) have been effective for the treatment of certain cancer types,<sup>1–4</sup> tumor neoantigens encoded by cancer-specific mutations emerged as major targets CD4+ CD8+ in immune checkpoint blockade (ICB) adoptive therapy (ACT).<sup>5–9</sup> However, only a minority intratumoral are reactive antigens while majority represent bystander cells.<sup>10–12</sup>...
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Supplementary Data from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
<div>Abstract<p>Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of ACT neoantigens, we focused on <i>TP53</i> mutations commonly shared across different cancer types. We performed whole-exome sequencing 163 metastatic solid cancers, identified 78 who had missense and through...